Other Resources
Biktarvy Fact Sheet from AIDSinfo
The U.S. Department of Health and Human Services (HHS) AIDSinfo site recently published a fact sheet on Biktarvy - a new one-pill-per-day HIV regimen that was approved by the U.S. Food and Drug Administration on February 7. The document provides extensive information about Biktarvy, including the drugs it contains, who it is approved for, drug dosing and what to do if someone misses a dose, and side effects, including the potential for serious adverse reactions. A Spanish version of the fact sheet is also available on HHS's infoSIDA site.
HHS Updates Opportunistic Infections Guidelines with New Information for Human Herpesvirus-8
The latest revision to HHS's Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents provides updated information about Human Herpesvirus-8 (HHV-8) - also known as Kaposi sarcoma-associated herpesvirus (KSHV). As its alternative name indicates, HHV-8 is the virus responsible for the AIDS-defining illness Kaposi's sarcoma, and it is also associated with a condition called multicentric Castleman's disease. The revised HHV-8 section includes the most recent data on the epidemiology of HHV-8 infection and HHV-8-related malignancies, new treatment recommendations for multicentric Castleman's disease, as well as information about a newly described clinical syndrome called the KSHV inflammatory cytokine syndrome (KICS).
CDC Fact Sheet and Web Pages
CDC recently published several new and updated HIV resources:
Internalized HIV-Related Stigma: This 2-page fact sheet describes internalized HIV-related stigma, its manifestations, and its prevalence by race/ethnicity, age, and gender. It also summarizes ways people living with HIV can reduce internalized HIV-related stigma.
HIV Among People Who Inject Drugs (PWID): This web page provides updated statistical data about HIV among PWID, including new HIV diagnoses and HIV prevalence. The page also describes challenges in preventing HIV infection among PWID and highlights CDC programs that support HIV surveillance, prevention, outbreak response, and treatment in this high-risk group.
Injection Drug Use and HIV Risk: This web page discusses the risk of HIV, other infections, and overdose among PWID. It also describes steps PWID can take to reduce the risks associated with injection drug use, and includes links to related resources on injection drug use, HIV, hepatitis C, and overdose prevention.
|